Oxygen therapy for cystic fibrosis

被引:25
|
作者
Elphick, Heather E. [1 ]
Mallory, George [2 ]
机构
[1] Sheffield Childrens Hosp, Resp Unit, Sheffield S10 2TH, S Yorkshire, England
[2] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2013年 / 07期
关键词
Oxygen Inhalation Therapy; Anoxia [etiology; mortality; therapy; Cystic Fibrosis [complications; Exercise Tolerance; Quality of Life; Randomized Controlled Trials as Topic; Sleep; Humans; NONINVASIVE VENTILATION; SUPPLEMENTAL OXYGEN; CHEST PHYSIOTHERAPY; PRESSURE SUPPORT; EXERCISE PERFORMANCE; PULMONARY-DISEASE; SLEEP; CHILDREN; DESATURATION; CAPACITY;
D O I
10.1002/14651858.CD003884.pub4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The most serious complications of cystic fibrosis (CF) relate to respiratory insufficiency. Oxygen supplementation therapy has long been a standard of care for individuals with chronic lung diseases associated with hypoxemia. Physicians commonly prescribe oxygen therapy for people with CF when hypoxemia occurs. However, it is unclear if empiric evidence is available to provide indications for this therapy with its financial costs and often profound impact on lifestyle. Objectives To assess whether oxygen therapy improves the longevity or quality of life of individuals with CF. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Latest search of Group's Trials Register: 15 May 2013. Selection criteria Randomized or quasi-randomized controlled trials comparing oxygen, administered at any concentration, by any route, in people with documented CF for any time period. Data collection and analysis Authors independently assessed the risk of bias for included studies and extracted data. Main results This review includes 11 published studies (172 participants); only one examined long-term oxygen therapy (28 participants). There was no statistically significant improvement in survival, lung, or cardiac health. There was an improvement in regular attendance at school or work in those receiving oxygen therapy at 6 and 12 months. Four studies examined the effect of oxygen supplementation during sleep by polysomnography. Although oxygenation improved, mild hypercapnia was noted. Participants fell asleep quicker and spent a reduced percentage of total sleep time in rapid eyemovement sleep, but there were no demonstrable improvements in qualitative sleep parameters. Six studies evaluated oxygen supplementation during exercise. Again, oxygenation improved, but mild hypercapnia resulted. Participants receiving oxygen therapy were able to exercise for a significantly longer duration during exercise. Other exercise parameters were not altered by the use of oxygen. Authors' conclusions There are no published data to guide the prescription of chronic oxygen supplementation to people with advanced lung disease due to CF. Short-term oxygen therapy during sleep and exercise improves oxygenation but is associated with modest and probably clinically inconsequential hypercapnia. There are improvements in exercise duration, time to fall asleep and regular attendance at school or work. There is a need for larger, well-designed clinical trials to assess the benefits of long-term oxygen therapy in people with CF administered continuously or during exercise or sleep or both.
引用
收藏
页数:50
相关论文
共 50 条
  • [31] Cell therapy for cystic fibrosis
    Murphy, Sean V.
    Atala, Anthony
    JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2015, 9 (03) : 210 - 223
  • [32] Ivacaftor therapy for cystic fibrosis
    McColley, Susanna A.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (11): : 1225 - 1232
  • [33] THERAPY OF CYSTIC-FIBROSIS
    NORDIO, S
    MARCHI, AG
    MINERVA PEDIATRICA, 1976, 28 (02) : 81 - 91
  • [34] Gene Therapy for Cystic Fibrosis
    Mueller, Christian
    Flotte, Terence R.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 35 (03) : 164 - 178
  • [35] Inhaled therapy in cystic fibrosis
    Braggion, Cesare
    Giuntini, Riccardo
    Cavicchi, Maria Chiara
    MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2007, 2 (01) : 93 - 97
  • [36] Azithromycin therapy in cystic fibrosis
    Carro, LM
    Moreno, RC
    MEDICINA CLINICA, 2004, 122 (08): : 311 - 316
  • [37] Gene therapy for cystic fibrosis
    Davies, JC
    Geddes, DM
    Alton, EWFW
    JOURNAL OF GENE MEDICINE, 2001, 3 (05): : 409 - 417
  • [38] Gene therapy for cystic fibrosis
    Caplen, NJ
    Alton, EWFW
    CHEMISTRY & INDUSTRY, 1996, (08) : 290 - 292
  • [39] Gene therapy for cystic fibrosis
    Kitson, C
    Alton, E
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (07) : 1523 - 1535
  • [40] Nebulisation therapy in patients with cystic fibrosis - consensus of the Polish Cystic Fibrosis Society
    Walicka-Serzysko, Katarzyna
    Orlik, Teresa
    Sands, Dorota
    Jeneralska, Natalia
    Popiel, Anna
    Skorupa, Wojciech
    Pogorzelski, Andrzej
    Cofta, Szczepan
    ADVANCES IN RESPIRATORY MEDICINE, 2021, 89 (06) : 570 - 580